Compositions and methods for ameliorating adverse effects of therapies
AssigneeMDX Management LLC
InventorsYuan LIU, Lei SHI, Zhen BIAN, Harry STYLLI
Life of this patent
Estimating the term…
Abstract
The present application provides a method of treating a cancer in an individual that involves administering to the individual a myeloid cell activating agent or therapy (such as a TLR agonist or a STING agonist) and a TNFα inhibitor. In some cases, the method further involves administering a SHP-1 inhibitor and/or tyrosine kinase inhibitor to the individual, optionally further administering a lymphocyte activating agent such as a cytokine (such as IL-2) and/or an immune checkpoint inhibitor (such as anti-PD-1).
Claims45
A method of treating a cancer in an individual, comprising administering to the individual a) a myeloid cell activating agent or therapy, and b) a TNFα inhibitor.
A method of treating a cancer in an individual, comprising administering to the individual a TNFα inhibitor and an inhibitor of the SHP-1 pathway, optionally wherein the individual is under an inflammation reaction, optionally wherein the inflammation reaction is characterized by
- a) an acute inflammation,
- b) a cytokine release syndrome, or
- c) an increased level of 1) at least two or three of TNFa, IL-6, IFN-g, and IFN-α, and/or 2) at least two or three of CCL2, CCL5, CXCL1, and CXCL10, further optionally wherein the inflammation reaction is characterized by an increased level of IL-2, IL-12, IL1b, and/or IL-10.
Dependencies are inferred from the claim text.